23:37 , Mar 26, 2019 |  BC Extra  |  Company News

Management tracks: Rubius, Abingworth, Arcus

Rubius hired Greg Whitehead as SVP and chief quality officer, a newly created position. He was VP, quality at bluebird bio Inc. (NASDAQ:BLUE). Whitehead will be responsible for defining the company's quality strategy to meet...
20:05 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

Aprea's MDS candidate leads to 95% ORR in Phase Ib/II

Aprea Therapeutics AB (Stockholm, Sweden) reported data from 20 evaluable patients with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) in a Phase Ib/II trial showing that APR-246 plus Vidaza azacitidine led to an overall...
18:14 , Dec 7, 2018 |  BC Week In Review  |  Financial News

Aprea heading for Phase III with €50M series C round

Aprea Therapeutics AB (Solna, Sweden) raised €50 million ($56.9 million) in a series C round on Nov. 30, with which it intends to fund a Phase III study of lead candidate APR-246 to treat myelodysplastic...
19:23 , Nov 30, 2018 |  BC Extra  |  Financial News

Aprea heading for Phase III with €50M series C round

Aprea Therapeutics AB (Solna, Sweden) raised €50 million ($56.9 million) in a series C round, with which it intends to fund a Phase III study of lead candidate APR-246 to treat myelodysplastic syndrome (MDS). The...
19:49 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

Aprea reports Phase Ib/II response data for APR-246 in MDS

Aprea Therapeutics AB (Stockholm, Sweden) said APR-246 plus Vidaza azacitidine led to an overall response rate (ORR) of 100%, including six complete responses and two marrow complete responses, in eight evaluable patients with myelodysplastic syndrome...
02:27 , Dec 8, 2017 |  BC Innovations  |  Translation in Brief

Multi-use p53 sensor

Scientists have made a synthetic gene circuit that senses lost or mutated p53, the tumor suppressor most commonly mutated in human cancers, and can be programmed to trigger a range of outputs, including expression of...
23:34 , Nov 2, 2017 |  BC Innovations  |  Targets & Mechanisms

Golden State of DUBs

Four papers in the last two weeks describing inhibitors of the ubiquitin-regulating protein USP7 could signal an important breakthrough in the ability to drug DUBs, a class of enzymes that has been stubbornly intractable until...
22:53 , May 26, 2017 |  BioCentury  |  Finance

Europe’s bellwether challenge

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....
19:51 , May 25, 2017 |  BC Week In Review  |  Clinical News

Aprea starts Phase Ib/II of APR-246 for MDS

Aprea Therapeutics AB (Solna, Sweden) began an open-label, U.S. Phase Ib/II trial to evaluate APR-246 in about 60 patients with tumor protein p53 ( TP53 ; p53) mutant myelodysplastic syndrome (MDS). The dose-escalation Phase I...
17:15 , Apr 13, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Esophageal cancer; cancer Cell culture and mouse studies suggest SLC7A11 inhibitors could help treat p53 -mutant esophageal cancer and other cancers that are resistant to p53 activators. In 10 p53-mutant esophageal cancer cell lines,...